Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency

BACKGROUND: Clinical trials showed limited benefit of anti-PD-1 (programmed cell death 1) monotherapy in pancreatic adenocarcinoma patients and immune-related adverse events caused by immune checkpoint inhibitors were rarely reported in pancreatic adenocarcinoma. Here, we report the first case of du...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Xionghao, Qian, Juanjuan, Jin, Hua, Zhang, Lei, Lin, Lin, Wang, Yuli, Lei, Yi, Zhou, Zeqiang, Li, Meixiang, Zhang, Henghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342819/
https://www.ncbi.nlm.nih.gov/pubmed/32636238
http://dx.doi.org/10.1136/jitc-2019-000463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342819/
https://www.ncbi.nlm.nih.gov/pubmed/32636238
http://dx.doi.org/10.1136/jitc-2019-000463

Ejemplares similares